Bio-Rad Laboratories, Inc. Share Price
Stocks
BIO
US0905722072
Medical Equipment, Supplies & Distribution
|
Real-time Estimate
Cboe BZX
08:31:30 03/09/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 383.52 USD | -1.28% |
|
-1.48% | +26.79% |
| 07/08 | RBC Adjusts PT on Bio-Rad Laboratories to $390 From $370, Maintains Outperform Rating | MT |
| 05/08 | RBC Adjusts Price Target on Bio-Rad Laboratories to $370 From $320, Maintains Outperform Rating | MT |
| Market Cap | 1.03TCr 885.95Cr 834.58Cr 760.4Cr 1.42TCr 97TCr 1.43TCr 9.88TCr 3.83TCr 50TCr 3.86TCr 3.77TCr 1,62900Cr | P/E 2026 * |
46.6x | P/E 2027 * | 45.7x |
|---|---|---|---|---|---|
| Enterprise Value | 952.05Cr 821.33Cr 773.71Cr 704.94Cr 1.32TCr 90TCr 1.33TCr 9.16TCr 3.55TCr 46TCr 3.58TCr 3.5TCr 1,51000Cr | EV / Sales 2026 * |
3.7x | EV / Sales 2027 * | 3.53x |
| Free-Float |
60.2% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
NYSE
| BIO | Delayed | |
CBOE
| BIO | Real-time | |
|
Deutsche Boerse AG
| BUWA | Delayed | |
|
Tradegate
| BUWA | Real-time | |
|
Börse Stuttgart
| BUWA | Delayed | |
|
Boerse Muenchen
| BUWA | Real-time |
Last Transcript : Bio-Rad Laboratories, Inc.
| 1 day | -1.28% | ||
| 1 week | -1.48% | ||
| Current month | -0.51% | ||
| 1 month | +14.77% | ||
| 3 months | +26.02% | ||
| 6 months | +37.10% | ||
| Current year | +26.79% |
| 1 week | 380.22 |  | 394.29 |
| 1 month | 325.31 | | 396.23 |
| Current year | 236.73 | | 396.23 |
| 1 year | 236.73 | | 396.23 |
| 3 years | 211.43 | | 396.23 |
| 5 years | 211.43 | | 822.09 |
| 10 years | 148.81 | | 832.7 |
| Manager | Title | Age | Since |
|---|---|---|---|
Norman Schwartz
CEO | Chief Executive Officer | 76 | 01/01/2003 |
| President | 61 | 09/09/2024 | |
Roop Lakkaraju
DFI | Director of Finance/CFO | 55 | 15/04/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Norman Schwartz
CHM | Chairman | 76 | 01/01/2012 |
Jeffrey Edwards
BRD | Director/Board Member | 73 | 25/04/2017 |
Gregory Hinckley
BRD | Director/Board Member | 79 | 25/04/2017 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 25/07/26 | Exercice | Executive/Senior Manager | 581 | 0.0027% | ||
| 11/05/26 | Sell | Executive/Senior Manager | -550 | 0.0025% | ||
| 24/04/26 | Exercice | General Counsel | 449 | 0.0020% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.28% | -1.48% | +33.36% | +0.50% | 1.03TCr | |
| -1.81% | -2.88% | -18.01% | +7.43% | 19TCr | |
| -0.55% | +1.42% | -1.08% | +13.78% | 12TCr | |
| -0.15% | +4.58% | +13.83% | +94.34% | 6.42TCr | |
| +0.16% | -2.02% | +26.41% | +50.66% | 5.15TCr | |
| -0.73% | -0.96% | -1.74% | -31.72% | 5.11TCr | |
| -0.25% | 0.00% | +13.14% | -11.00% | 3.38TCr | |
| -0.95% | +3.35% | - | - | 3.18TCr | |
| -0.36% | -1.87% | +36.42% | -15.87% | 2.41TCr | |
| -0.06% | -4.06% | -7.43% | +11.58% | 2.3TCr | |
| Average | -0.62% | -0.82% | +10.54% | +13.30% | 5.99TCr | |
| Weighted average by Cap. | -0.89% | -1.92% | +0.15% | +16.94% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 257.33Cr 222Cr 209.13Cr 190.54Cr 356.15Cr 24TCr 358.82Cr 2.48TCr 960.88Cr 12TCr 966.31Cr 945.18Cr 41TCr | 263.35Cr 227.19Cr 214.02Cr 195Cr 364.48Cr 25TCr 367.21Cr 2.53TCr 983.35Cr 13TCr 988.9Cr 967.28Cr 42TCr |
| Net income | 22Cr 19Cr 18Cr 17Cr 31Cr 2.13TCr 31Cr 216.48Cr 84Cr 1.09TCr 84Cr 83Cr 3.57TCr | 23Cr 20Cr 19Cr 17Cr 32Cr 2.17TCr 32Cr 221.29Cr 86Cr 1.11TCr 86Cr 84Cr 3.65TCr |
| Net Debt | -75Cr -65Cr -61Cr -55Cr -103.67Cr -7.08TCr -104.44Cr -720.66Cr -279.68Cr -3.62TCr -281.26Cr -275.11Cr -12TCr | -97Cr -83Cr -78Cr -71Cr -133.62Cr -9.12TCr -134.62Cr -928.87Cr -360.49Cr -4.66TCr -362.52Cr -354.6Cr -15TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/26/03 | $384.90 | -0.93% | 19,741 |
| 02/26/02 | $388.51 | +1.98% | 2,85,333 |
| 01/26/01 | $380.96 | -1.34% | 2,56,110 |
| 31/26/31 | $386.12 | -0.41% | 3,01,423 |
| 28/26/28 | $387.70 | -0.57% | 2,06,972 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- BIO Stock
Select your edition
All financial news and data tailored to specific country editions
